Leiomyoma

6

Review clinical trials related to Leiomyoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery

A myomectomy is a surgery to remove noncancerous growths (fibroids) from the uterus while keeping the uterus in place. This surgery can cause significant blood loss. Terlipressin is a medicine that narrows blood vessels and may help reduce bleeding. This study will test whether injecting a diluted terlipressin solution under the outer covering of the fibroid, before it is removed, reduces the amount of blood lost during surgery, compared to an inactive solution (placebo). Women scheduled for myomectomy will be randomly assigned to receive either terlipressin or placebo. Neither the patients nor the surgical team will know which one was given until the study is finished. The main question this study will answer is how much blood is lost during surgery in each group.

Participants needed: 80
Trial details
Biological sex: FemaleType: InterventionalSponsor: Sevil CankayaUpdated: Aug 5, 2026
Eligibility criteria

Symptomatic uterine fibroid(s) with an indication for myomectomy, including meno... [+5]

History of bleeding disorders or coagulopathy [+12]

Status: Recruiting

Prescription of Letrozole for Uterine Myoma

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

Participants needed: 140
Trial details
Phase: Phase 4Age: 21-53Biological sex: FemaleType: InterventionalSponsor: University of California, San FranciscoUpdated: Jul 22, 2026Locations: 5
Eligibility criteria

At least 21 and less than 54 years of age (to focus on an adult, premenopausal p... [+6]

Screening pelvic imaging indicating any leiomyomata ≥10 cm in maximum diameter,... [+20]

Status: Recruiting

Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)

The investigators are evaluating the role of senescent cells in uterine fibroids.

Participants needed: 150
Trial details
Age: 18-55Biological sex: FemaleType: ObservationalSponsor: Johns Hopkins UniversityUpdated: Dec 11, 2025Locations: 1
Eligibility criteria

Subjects must be women above the age of ≥18 - ≤55 years. [+3]

Unwilling to sign the consent form or complete questionnaire. [+2]

Status: Recruiting

An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validated questionnaires at scheduled timepoints to assess symptom severity and quality of life.

Participants needed: 42
Trial details
Age: 20-45Biological sex: FemaleType: InterventionalSponsor: Zenchi, Inc.Updated: Sep 12, 2025Locations: 1
Eligibility criteria

Be female. [+15]

Does not experience a regular menstrual cycle (21-35 days). [+24]

Status: Not yet recruiting

CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study

The investigators conduct a prospective, multicenter diagnostic trial primarily aimed at evaluating the value of contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) in differentiating gastrointestinal stromal tumors (GISTs) from leiomyomas, as well as its predictive utility in the risk stratification of GISTs.

Participants needed: 288
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: Huazhong University of Science and TechnologyUpdated: Aug 6, 2025Locations: 1
Eligibility criteria

Age ≥18 years and ≤ 85 years; [+6]

Age <18 years or >85 years; [+5]

Status: Recruiting

Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis

This study develops a multimodal AI model using endoscopic ultrasound, white-light endoscopy, and clinical information to support the diagnosis of upper GI mesenchymal tumors and the risk stratification of gastric GISTs.

Participants needed: 130
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Huazhong University of Science and TechnologyUpdated: Jul 31, 2025Locations: 1
Eligibility criteria

Age ≥ 18 years old [+9]

Age < 18 years old [+5]